Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neville F Ford

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
The Journal of Invasive Cardiology|August 2, 2015
Clopidogrel and GenotypingNeville F Ford
Journal of Clinical Pharmacology|February 28, 2009
Clopidogrel resistance: pharmacokinetic or pharmacogenetic?Neville F Ford
Journal of Clinical Pharmacology|May 20, 2016
The Metabolism of Clopidogrel: CYP2C19 Is a Minor PathwayNeville F Ford
Journal of Clinical Pharmacology|May 15, 2014
Clopidogrel: what is a cardiologist to do?Neville F Ford
Journal of Clinical Pharmacology|February 6, 2013
Clopidogrel, CYP2C19, and a Black BoxNeville F Ford, Dirk Taubert
BMJ (Clinical Research Ed.)|August 6, 2011
Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysisTim Bauer, Heleen J Bouman, Jochem W van Werkum, et al.
British Journal of Clinical Pharmacology|November 25, 2005
Vasodilator effects of the endothelin ET receptor selective antagonist BMS-193884 in healthy menNeeraj Dhaun, Fiona E Strachan, David E Newby, et al.
Archives of Internal Medicine|January 14, 2004
Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analysesCharles H Hennekens, Frank M Sacks, Andrew Tonkin, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
The Journal of Invasive Cardiology|August 2, 2015
Clopidogrel and GenotypingNeville F Ford
Journal of Clinical Pharmacology|February 28, 2009
Clopidogrel resistance: pharmacokinetic or pharmacogenetic?Neville F Ford
Journal of Clinical Pharmacology|May 20, 2016
The Metabolism of Clopidogrel: CYP2C19 Is a Minor PathwayNeville F Ford
Journal of Clinical Pharmacology|May 15, 2014
Clopidogrel: what is a cardiologist to do?Neville F Ford
Journal of Clinical Pharmacology|February 6, 2013
Clopidogrel, CYP2C19, and a Black BoxNeville F Ford, Dirk Taubert
BMJ (Clinical Research Ed.)|August 6, 2011
Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysisTim Bauer, Heleen J Bouman, Jochem W van Werkum, et al.
British Journal of Clinical Pharmacology|November 25, 2005
Vasodilator effects of the endothelin ET receptor selective antagonist BMS-193884 in healthy menNeeraj Dhaun, Fiona E Strachan, David E Newby, et al.
Archives of Internal Medicine|January 14, 2004
Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analysesCharles H Hennekens, Frank M Sacks, Andrew Tonkin, et al.
Pageof 1